All Stories

  1. New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol
  2. Modeling Longitudinal Relationships Between CKD-MBD Biomarker Trajectories with Interpretable Machine Learning in a Large Prospective CKD Cohort
  3. How to perform a renal transplant biopsy: a practical guide for clinicians with CEUS-driven diagnosis and follow-up of complications
  4. Sodium load of novel antibiotics: considerations for nephrologists and clinicians
  5. Experience in Peritoneal Dialysis
  6. Usability of machine learning algorithms based on electronic health records for the prediction of acute kidney injury and transition to acute kidney disease: A proof of concept study
  7. Pathophysiology of chronic kidney disease–mineral bone disorder (CKD-MBD): from adaptive to maladaptive mineral homeostasis
  8. Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease
  9. Bioimpedance Analysis in CKD and HF Patients: A Critical Review of Benefits, Limitations, and Future Directions
  10. Phosphorous metabolism and manipulation in chronic kidney disease
  11. Cardiovascular calcification and renal function: A dysfunctional liaison
  12. Performance of [18F]FDG PET/CT in Diagnosing Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and a Bivariate Meta-Analysis
  13. Papillary necrosis, fluid intake, and sickle cell nephropathy: lessons for the clinical nephrologist
  14. Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease–mineral and bone disorder
  15. QTc interval prolongation independently associates with FGF23 and predicts mortality in predialysis CKD.
  16. New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
  17. Peritoneal dialysis discontinuation: to the root of the problem
  18. Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
  19. The Impact of Cholecaciferol Supplementation on Bone Mineral Density in Long-Term Kidney Transplant Recipients
  20. Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study
  21. Early Neurological ASsessment with pupillometrY during Cardiac Arrest REsuscitation (EASY-CARE): protocol for an observational multicentre prospective study
  22. What electronic health records can and cannot tell us in the era of big data
  23. The “FIFTY SHADOWS” of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease
  24. Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study
  25. Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study)
  26. Bone Mineral Density Changes in Long-Term Kidney Transplant Recipients: A Real-Life Cohort Study of Native Vitamin D Supplementation
  27. Retinal endothelial dysfunction: A glance on long-term risk of kidney failure
  28. Twelve-lead electrocardiogram artefacts in patients with arteriovenous fistulas for haemodialysis
  29. Bone metabolism and cardiovascular disease: An overlooked association?
  30. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19
  31. Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients
  32. Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis
  33. Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients
  34. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
  35. Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study
  36. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
  37. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study
  38. Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study
  39. Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019
  40. English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?
  41. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium
  42. Is peritoneal dialysis superior to hemodialysis as far as cardiovascular risk? Another unsolved dilemma for maintenance dialysis
  43. Feasibility of routine ultrasound-guided percutaneous transluminal angioplasty in the treatment of native arteriovenous fistula dysfunction
  44. Glifozines and cardiorenal outcomes
  45. Correction to: Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study
  46. Kidney Diseases: Challenges and Opportunities of the Third Millenium. How can digital health help the National Health System?
  47. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis
  48. Therapeutic management of HIV-infected patients with chronic kidney disease
  49. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network
  50. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
  51. Associations between echocardiographic findings and prospective changes in residual renal function in patients new to peritoneal dialysis
  52. Mineral and Electrolyte Disorders With SGLT2i Therapy
  53. Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification
  54. Chronic Kidney Disease: The Silent Epidemy
  55. Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients
  56. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study
  57. Implication of Acute Kidney Injury in Heart Failure
  58. Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study)
  59. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial
  60. Kidney Disease in HIV Infection
  61. Fractional Excretion of Phosphate (FeP) Is Associated with End-Stage Renal Disease Patients with CKD 3b and 5
  62. Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights
  63. Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor
  64. Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus
  65. Classification of Cardiorenal Syndrome
  66. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?
  67. Cardiorenal Syndrome in Acute Kidney Injury
  68. Coronary artery calcium in the general population, patients with chronic kidney disease and diabetes mellitus
  69. Chronic kidney disease: A model of impaired vascular remodeling
  70. Search for a reliable biomarker of acute kidney injury: to the heart of the problem
  71. Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options
  72. Cardiorenal Syndrome: An Overview
  73. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data
  74. Cardiovascular calcification: The emerging role of micronutrients
  75. Among markers of risk, uric acid remains a two-faced Janus awaiting definitive framing
  76. Vascular inflammation: A call for a specific and sensitive biomarker?
  77. CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy
  78. Intervista ad Antonio Bellasi
  79. Nutritional therapy in autosomal dominant polycystic kidney disease
  80. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents
  81. Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
  82. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease
  83. Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease
  84. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation
  85. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
  86. Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
  87. Epidemiology of low-proteinuric chronic kidney disease in renal clinics
  88. Assessment of intradialysis calcium mass balance by a single pool variable-volume calcium kinetic model
  89. Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment
  90. Type-5 cardiorenal syndrome (CRS-5): an up to date
  91. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease
  92. Prediction of hard cardiovascular events in HIV patients
  93. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies
  94. The density of calcified plaques and the volume of calcium predict mortality in hemodialysis patients
  95. Shed a light on intradialytic calcium mass balance
  96. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial
  97. Serum calcium may not accurately predict intradialytic calcium mass transfer
  98. Opponent's comments
  99. Coronary artery disease (CAD) in chronic kidney disease patients
  100. Retarding CKD Progression: Readily Available through Comprehensive Nutritional Management?
  101. Single-Center Open-Label Randomized Study of Anemia Management Improvement in ESRD Patients with Secondary Hyperparathyroidism
  102. Pro: Should phosphate binders be used in chronic kidney disease stage 3–4?Opponent's comments
  103. Con: Phosphate binders in chronic kidney diseaseOpponent's comments
  104. Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients
  105. EPICARDIAL ADIPOSE TISSUE AND CORONARY ARTERY CALCIUM INDEPENDENTLY PREDICT INCIDENT MYOCARDIAL INFARCTION AND DEATH IN HIV-INFECTED PATIENTS
  106. Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease
  107. SP575PREDICTIVE VALUE OF MEASURES OF VASCULAR CALCIFICATION FOR RISK OF DEATH IN INCIDENT DIALYSIS PATIENTS
  108. Emerging drugs for secondary hyperparathyroidism
  109. Opponent's comments
  110. The Importance of Ventricular-Vascular Uncoupling
  111. Cardiovascular Biomarkers in Chronic Kidney Disease: State of Current Research and Clinical Applicability
  112. Ivabradine, Heart Failure and Chronic Kidney Disease
  113. Nephrology@Point of Care: A New Journal for Hands-On Clinicians
  114. Vascular calcification, bone and mineral metabolism after kidney transplantation
  115. Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients
  116. Not all diabetic patients were created equal: How to discriminate risk?
  117. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
  118. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
  119. Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?
  120. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease
  121. Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study
  122. Physical Activity in Chronic Kidney Disease: a Plausible Approach to Vascular Calcification?
  123. Hybrid myocardial imaging for risk stratification prior to kidney transplantation: Added value of coronary calcium and epicardial adipose tissue
  124. Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial
  125. Hybrid Myocardial Imaging for Cardiovascular Risk Stratification Prior to Kidney Transplantation: Added Value of Coronary Calcium and Epicardial Adipose Tissue
  126. Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients
  127. Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias
  128. Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial
  129. Cinacalcet: the chemical parathyroidectomy?
  130. QT interval in CKD and haemodialysis patients
  131. Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice
  132. Does It Make Sense to Measure Only the Brachial Blood Pressure?
  133. Which Vitamin D in CKD-MBD? The Time of Burning Questions
  134. Phosphate balance and organ damage
  135. Phosphate binders in moderate chronic kidney disease: where do we stand?
  136. Vitamin D Status and Coronary Flow Reserve Measured by Positron Emission Tomography: A Co-Twin Control Study
  137. Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease?
  138. Report from 1st National Meeting of Cardionephrology Study Group of Italian Society of Nephrology
  139. Subendocardial Viability Ratio Predicts Cardiovascular Mortality in Chronic Kidney Disease Patients
  140. Arterial Stiffness, Pulse Wave Analyses: What Can’t Blood Pressure Tell you in Chronic Kidney Disease
  141. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients
  142. Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease
  143. Blood pressure variability and outcomes in chronic kidney disease
  144. Vascular imaging in chronic kidney disease
  145. Integration of clinical and imaging data to predict death in hemodialysis patients
  146. Bone and mineral diseases - 2
  147. Mortality in Kidney Disease Patients Treated with Phosphate Binders: A Randomized Study
  148. Impact of Vascular Calcification on QT Interval and QT Dispersion in CKD and Dialysis Patients
  149. Is time on cardiopulmonary bypass during cardiac surgery associated with acute kidney injury requiring dialysis?
  150. All-cause Mortality in Hemodialysis Patients with Heart Valve Calcification
  151. Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients
  152. Variability of pulse wave velocity and mortality in chronic hemodialysis patients
  153. Intervista ad Antonio Bellasi
  154. Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction
  155. Coronary Artery Calcification Progression Is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients
  156. Arterial Stiffness in Chronic Kidney Disease: The Usefulness of a Marker of Vascular Damage
  157. Vascular calcification in chronic kidney disease: usefulness of a marker of vascular damage
  158. La calcificazione vascolare nel paziente con insufficienza renale cronica
  159. Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
  160. Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry)
  161. Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality
  162. Phosphorus levels are associated with subclinical atherosclerosis in the general population
  163. Impact of race and chronic kidney disease on 1-year outcome in patients undergoing percutaneous coronary interventions: A single tertiary center experience
  164. Markers of vascular disease do not differ in black and white hemodialysis patients despite a different risk profile
  165. Phosphate Binders
  166. Cardiovascular Calcium: Assessment and Impact of Interventions
  167. New insights into ischemic heart disease in women.
  168. Comparison of Prognostic Usefulness of Coronary Artery Calcium in Men Versus Women (Results from a Meta- and Pooled Analysis Estimating All-Cause Mortality and Coronary Heart Disease Death or Myocardial Infarction)
  169. Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus
  170. Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients
  171. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients
  172. VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Techniques and Technologies to Assess Vascular Calcification
  173. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients
  174. Clinical Assessment of Vascular Calcification
  175. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis
  176. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients
  177. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders
  178. Development of a cardiovascular calcification index using simple imaging tools in haemodialysis patients
  179. Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions
  180. Phosphate binders: New products and challenges
  181. Ischemia Imaging and Plaque Imaging in Diabetes: Complementary Tools to Improve Cardiovascular Risk Management
  182. Phosphate binders
  183. Ischemia Imaging and Plaque Imaging in Diabetes
  184. Diagnostic and prognostic value of coronary artery calcium screening
  185. Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
  186. Coronary Artery Calcium Screening: Implications for Clinical Practice
  187. Salvage Insertion of Tunneled Central Venous Catheters in the Internal Jugular Vein after Accidental Catheter Removal